APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical (Oral Route)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radiopharmaceutical (Oral Route) Market Outlook and Growth Opportunities 2026

Report ID 174030640431 December 2025197 pages

Choose your research edition.

Industry ResearchRadiopharmaceutical (Oral Route) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical (Oral Route) Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical (Oral Route) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical (Oral Route) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical (Oral Route) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Radiopharmaceutical (Oral Route) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radiopharmaceutical (Oral Route) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radiopharmaceutical (Oral Route) market include Eli Lilly, Bayer, Triad Isotopes, SIEMENS, Nordion, Navidea, Mallinckrodt, Lantheus and Jubilant Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Radiopharmaceutical (Oral Route) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceutical (Oral Route) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceutical (Oral Route) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceutical (Oral Route) market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiopharmaceutical (Oral Route) Segment by Company

Eli Lilly

Bayer

Triad Isotopes

SIEMENS

Nordion

Navidea

Mallinckrodt

Lantheus

Jubilant Pharma

IBA Group

GE Healthcare

Dongcheng

China Isotope & Radiation

Bracco Imaging

Advanced Accelerator Applications

Radiopharmaceutical (Oral Route) Segment by Type

Actinium-225

Holmium-166

Radium-223

Lutetium-177

Other

Radiopharmaceutical (Oral Route) Segment by Application

Oncology

Cardiology

Other

Radiopharmaceutical (Oral Route) Segment by Region

North America

United States

Canada

Europe

v

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Radiopharmaceutical (Oral Route) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Radiopharmaceutical (Oral Route) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiopharmaceutical (Oral Route) significant trends, drivers, influence factors in global and regions.

6. To analyze Radiopharmaceutical (Oral Route) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical (Oral Route).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceutical (Oral Route) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceutical (Oral Route) industry.

Chapter 3: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Radiopharmaceutical (Oral Route) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Radiopharmaceutical (Oral Route) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceutical (Oral Route) Industry Trends Table 2. Radiopharmaceutical (Oral Route) Industry Drivers Table 3. Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges Table 4. Radiopharmaceutical (Oral Route) Industry Restraints Table 5. Global Radiopharmaceutical (Oral Route) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceutical (Oral Route) Revenue Share by Company (2021-2026) Table 7. Global Radiopharmaceutical (Oral Route) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Company (2021-2026) Table 9. Global Radiopharmaceutical (Oral Route) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Radiopharmaceutical (Oral Route) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Radiopharmaceutical (Oral Route) Key Company Manufacturing Base & Headquarters Table 12. Global Radiopharmaceutical (Oral Route) Company, Product Type & Application Table 13. Global Radiopharmaceutical (Oral Route) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiopharmaceutical (Oral Route) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Actinium-225 Table 18. Significant Companies of Holmium-166 Table 19. Significant Companies of Radium-223 Table 20. Significant Companies of Lutetium-177 Table 21. Significant Companies of Other Table 22. Global Radiopharmaceutical (Oral Route) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Type (2021-2026) Table 26. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Type (2027-2032) Table 27. Global Radiopharmaceutical (Oral Route) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Radiopharmaceutical (Oral Route) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Radiopharmaceutical (Oral Route) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Radiopharmaceutical (Oral Route) Sales Value Share by Type (2021-2026) Table 31. Global Radiopharmaceutical (Oral Route) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Oncology Table 33. Significant Companies of Cardiology Table 34. Significant Companies of Other Table 35. Global Radiopharmaceutical (Oral Route) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Application (2021-2026) Table 39. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Application (2027-2032) Table 40. Global Radiopharmaceutical (Oral Route) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Radiopharmaceutical (Oral Route) Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Radiopharmaceutical (Oral Route) Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Radiopharmaceutical (Oral Route) Sales Value Share by Application (2021-2026) Table 44. Global Radiopharmaceutical (Oral Route) Sales Value Share by Application (2027-2032) Table 45. Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2026) & (K Units) Table 47. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2021-2026) Table 48. Global Radiopharmaceutical (Oral Route) Sales by Region (2027-2032) & (K Units) Table 49. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2027-2032) Table 50. Global Radiopharmaceutical (Oral Route) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Radiopharmaceutical (Oral Route) Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Radiopharmaceutical (Oral Route) Sales Value Share by Region (2021-2026) Table 53. Global Radiopharmaceutical (Oral Route) Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Radiopharmaceutical (Oral Route) Sales Value Share by Region (2027-2032) Table 55. Global Radiopharmaceutical (Oral Route) Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Radiopharmaceutical (Oral Route) Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Radiopharmaceutical (Oral Route) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Radiopharmaceutical (Oral Route) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 60. Global Radiopharmaceutical (Oral Route) Sales Market Share by Country (2021-2026) Table 61. Global Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 62. Global Radiopharmaceutical (Oral Route) Sales Market Share by Country (2027-2032) Table 63. Global Radiopharmaceutical (Oral Route) Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Radiopharmaceutical (Oral Route) Sales Value Market Share by Country (2021-2026) Table 65. Global Radiopharmaceutical (Oral Route) Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Radiopharmaceutical (Oral Route) Sales Value Market Share by Country (2027-2032) Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Bayer Company Information Table 73. Bayer Business Overview Table 74. Bayer Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bayer Radiopharmaceutical (Oral Route) Product Portfolio Table 76. Bayer Recent Development Table 77. Triad Isotopes Company Information Table 78. Triad Isotopes Business Overview Table 79. Triad Isotopes Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio Table 81. Triad Isotopes Recent Development Table 82. SIEMENS Company Information Table 83. SIEMENS Business Overview Table 84. SIEMENS Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio Table 86. SIEMENS Recent Development Table 87. Nordion Company Information Table 88. Nordion Business Overview Table 89. Nordion Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Nordion Radiopharmaceutical (Oral Route) Product Portfolio Table 91. Nordion Recent Development Table 92. Navidea Company Information Table 93. Navidea Business Overview Table 94. Navidea Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Navidea Radiopharmaceutical (Oral Route) Product Portfolio Table 96. Navidea Recent Development Table 97. Mallinckrodt Company Information Table 98. Mallinckrodt Business Overview Table 99. Mallinckrodt Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio Table 101. Mallinckrodt Recent Development Table 102. Lantheus Company Information Table 103. Lantheus Business Overview Table 104. Lantheus Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Lantheus Radiopharmaceutical (Oral Route) Product Portfolio Table 106. Lantheus Recent Development Table 107. Jubilant Pharma Company Information Table 108. Jubilant Pharma Business Overview Table 109. Jubilant Pharma Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio Table 111. Jubilant Pharma Recent Development Table 112. IBA Group Company Information Table 113. IBA Group Business Overview Table 114. IBA Group Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. IBA Group Radiopharmaceutical (Oral Route) Product Portfolio Table 116. IBA Group Recent Development Table 117. GE Healthcare Company Information Table 118. GE Healthcare Business Overview Table 119. GE Healthcare Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio Table 121. GE Healthcare Recent Development Table 122. Dongcheng Company Information Table 123. Dongcheng Business Overview Table 124. Dongcheng Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio Table 126. Dongcheng Recent Development Table 127. China Isotope & Radiation Company Information Table 128. China Isotope & Radiation Business Overview Table 129. China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio Table 131. China Isotope & Radiation Recent Development Table 132. Bracco Imaging Company Information Table 133. Bracco Imaging Business Overview Table 134. Bracco Imaging Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio Table 136. Bracco Imaging Recent Development Table 137. Advanced Accelerator Applications Company Information Table 138. Advanced Accelerator Applications Business Overview Table 139. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio Table 141. Advanced Accelerator Applications Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Radiopharmaceutical (Oral Route) Distributors List Table 145. Radiopharmaceutical (Oral Route) Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Radiopharmaceutical (Oral Route) Product Image Figure 2. Global Radiopharmaceutical (Oral Route) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceutical (Oral Route) Sales (2021-2032) & (K Units) Figure 5. Global Radiopharmaceutical (Oral Route) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Radiopharmaceutical (Oral Route) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Actinium-225 Image Figure 10. Holmium-166 Image Figure 11. Radium-223 Image Figure 12. Lutetium-177 Image Figure 13. Other Image Figure 14. Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Radiopharmaceutical (Oral Route) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Type (2021-2032) Figure 17. Global Radiopharmaceutical (Oral Route) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Radiopharmaceutical (Oral Route) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Radiopharmaceutical (Oral Route) Sales Value Share by Type (2021-2032) Figure 20. Oncology Image Figure 21. Cardiology Image Figure 22. Other Image Figure 23. Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Radiopharmaceutical (Oral Route) Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Radiopharmaceutical (Oral Route) Sales Volume Share by Application (2021-2032) Figure 26. Global Radiopharmaceutical (Oral Route) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Radiopharmaceutical (Oral Route) Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Radiopharmaceutical (Oral Route) Sales Value Share by Application (2021-2032) Figure 29. Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Radiopharmaceutical (Oral Route) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Radiopharmaceutical (Oral Route) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 34. North America Radiopharmaceutical (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Radiopharmaceutical (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Radiopharmaceutical (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 40. South America Radiopharmaceutical (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Radiopharmaceutical (Oral Route) Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Radiopharmaceutical (Oral Route) Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Actinium-225
  • Holmium-166
  • Radium-223
  • Lutetium-177
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Eli Lilly
  • Bayer
  • Triad Isotopes
  • SIEMENS
  • Nordion
  • Navidea
  • Mallinckrodt
  • Lantheus
  • Jubilant Pharma
  • IBA Group
  • GE Healthcare
  • Dongcheng
  • China Isotope & Radiation
  • Bracco Imaging
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  4. 1.2.2 Global Radiopharmaceutical (Oral Route) Sales Volume (2021-2032)
  5. 1.2.3 Global Radiopharmaceutical (Oral Route) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Radiopharmaceutical (Oral Route) Market Dynamics
  1. 2.1 Radiopharmaceutical (Oral Route) Industry Trends
  2. 2.2 Radiopharmaceutical (Oral Route) Industry Drivers
  3. 2.3 Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical (Oral Route) Industry Restraints
3 Radiopharmaceutical (Oral Route) Market by Company
  1. 3.1 Global Radiopharmaceutical (Oral Route) Company Revenue Ranking in 2025
  2. 3.2 Global Radiopharmaceutical (Oral Route) Revenue by Company (2021-2026)
  3. 3.3 Global Radiopharmaceutical (Oral Route) Sales Volume by Company (2021-2026)
  4. 3.4 Global Radiopharmaceutical (Oral Route) Average Price by Company (2021-2026)
  5. 3.5 Global Radiopharmaceutical (Oral Route) Company Ranking (2024-2026)
  6. 3.6 Global Radiopharmaceutical (Oral Route) Company Manufacturing Base and Headquarters
  7. 3.7 Global Radiopharmaceutical (Oral Route) Company Product Type and Application
  8. 3.8 Global Radiopharmaceutical (Oral Route) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Radiopharmaceutical (Oral Route) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Radiopharmaceutical (Oral Route) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceutical (Oral Route) Market by Type
  1. 4.1 Radiopharmaceutical (Oral Route) Type Introduction
  2. 4.1.1 Actinium-225
  3. 4.1.2 Holmium-166
  4. 4.1.3 Radium-223
  5. 4.1.4 Lutetium-177
  6. 4.1.5 Other
  7. 4.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Type
  8. 4.2.1 Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Radiopharmaceutical (Oral Route) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Radiopharmaceutical (Oral Route) Sales Value by Type
  12. 4.3.1 Global Radiopharmaceutical (Oral Route) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Radiopharmaceutical (Oral Route) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Radiopharmaceutical (Oral Route) Sales Value Share by Type (2021-2032)
5 Radiopharmaceutical (Oral Route) Market by Application
  1. 5.1 Radiopharmaceutical (Oral Route) Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Application
  6. 5.2.1 Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceutical (Oral Route) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Radiopharmaceutical (Oral Route) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Radiopharmaceutical (Oral Route) Sales Value by Application
  10. 5.3.1 Global Radiopharmaceutical (Oral Route) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Radiopharmaceutical (Oral Route) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Radiopharmaceutical (Oral Route) Sales Value Share by Application (2021-2032)
6 Radiopharmaceutical (Oral Route) Regional Sales and Value Analysis
  1. 6.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021-2026
  4. 6.2.2 Global Radiopharmaceutical (Oral Route) Sales by Region (2027-2032)
  5. 6.3 Global Radiopharmaceutical (Oral Route) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Radiopharmaceutical (Oral Route) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Radiopharmaceutical (Oral Route) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Radiopharmaceutical (Oral Route) Sales Value by Region (2027-2032)
  9. 6.5 Global Radiopharmaceutical (Oral Route) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  12. 6.6.2 North America Radiopharmaceutical (Oral Route) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  15. 6.7.2 Europe Radiopharmaceutical (Oral Route) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Radiopharmaceutical (Oral Route) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  21. 6.9.2 South America Radiopharmaceutical (Oral Route) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Radiopharmaceutical (Oral Route) Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceutical (Oral Route) Country-level Sales and Value Analysis
  1. 7.1 Global Radiopharmaceutical (Oral Route) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiopharmaceutical (Oral Route) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
  4. 7.3.1 Global Radiopharmaceutical (Oral Route) Sales by Country (2021-2026)
  5. 7.3.2 Global Radiopharmaceutical (Oral Route) Sales by Country (2027-2032)
  6. 7.4 Global Radiopharmaceutical (Oral Route) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Radiopharmaceutical (Oral Route) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Radiopharmaceutical (Oral Route) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Radiopharmaceutical (Oral Route) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Radiopharmaceutical (Oral Route) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Radiopharmaceutical (Oral Route) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Triad Isotopes
  14. 8.3.1 Triad Isotopes Company Information
  15. 8.3.2 Triad Isotopes Business Overview
  16. 8.3.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
  18. 8.3.5 Triad Isotopes Recent Developments
  19. 8.4 SIEMENS
  20. 8.4.1 SIEMENS Company Information
  21. 8.4.2 SIEMENS Business Overview
  22. 8.4.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
  24. 8.4.5 SIEMENS Recent Developments
  25. 8.5 Nordion
  26. 8.5.1 Nordion Company Information
  27. 8.5.2 Nordion Business Overview
  28. 8.5.3 Nordion Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
  30. 8.5.5 Nordion Recent Developments
  31. 8.6 Navidea
  32. 8.6.1 Navidea Company Information
  33. 8.6.2 Navidea Business Overview
  34. 8.6.3 Navidea Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
  36. 8.6.5 Navidea Recent Developments
  37. 8.7 Mallinckrodt
  38. 8.7.1 Mallinckrodt Company Information
  39. 8.7.2 Mallinckrodt Business Overview
  40. 8.7.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
  42. 8.7.5 Mallinckrodt Recent Developments
  43. 8.8 Lantheus
  44. 8.8.1 Lantheus Company Information
  45. 8.8.2 Lantheus Business Overview
  46. 8.8.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
  48. 8.8.5 Lantheus Recent Developments
  49. 8.9 Jubilant Pharma
  50. 8.9.1 Jubilant Pharma Company Information
  51. 8.9.2 Jubilant Pharma Business Overview
  52. 8.9.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
  54. 8.9.5 Jubilant Pharma Recent Developments
  55. 8.10 IBA Group
  56. 8.10.1 IBA Group Company Information
  57. 8.10.2 IBA Group Business Overview
  58. 8.10.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
  60. 8.10.5 IBA Group Recent Developments
  61. 8.11 GE Healthcare
  62. 8.11.1 GE Healthcare Company Information
  63. 8.11.2 GE Healthcare Business Overview
  64. 8.11.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
  66. 8.11.5 GE Healthcare Recent Developments
  67. 8.12 Dongcheng
  68. 8.12.1 Dongcheng Company Information
  69. 8.12.2 Dongcheng Business Overview
  70. 8.12.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
  72. 8.12.5 Dongcheng Recent Developments
  73. 8.13 China Isotope & Radiation
  74. 8.13.1 China Isotope & Radiation Company Information
  75. 8.13.2 China Isotope & Radiation Business Overview
  76. 8.13.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
  78. 8.13.5 China Isotope & Radiation Recent Developments
  79. 8.14 Bracco Imaging
  80. 8.14.1 Bracco Imaging Company Information
  81. 8.14.2 Bracco Imaging Business Overview
  82. 8.14.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
  84. 8.14.5 Bracco Imaging Recent Developments
  85. 8.15 Advanced Accelerator Applications
  86. 8.15.1 Advanced Accelerator Applications Company Information
  87. 8.15.2 Advanced Accelerator Applications Business Overview
  88. 8.15.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
  90. 8.15.5 Advanced Accelerator Applications Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiopharmaceutical (Oral Route) Value Chain Analysis
  2. 9.1.1 Radiopharmaceutical (Oral Route) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiopharmaceutical (Oral Route) Sales Mode & Process
  6. 9.2 Radiopharmaceutical (Oral Route) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiopharmaceutical (Oral Route) Distributors
  9. 9.2.3 Radiopharmaceutical (Oral Route) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst